ArticleBlood2021

Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.

Jessica T Leonard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.